IMAGING NEURAL CORRELATES OF FATIGUE & PAIN IN PATIENTS WITH RA TREATED WITH TNF INHIBITORS FARHAN BARI SPR RHEUMATOLOGY WARN CONFERENCE 22 ND MAY 2014.

Slides:

Advertisements

Similar presentations

Responding to the Patient’s Voice: the importance of Patient Reported Outcomes Dr. Kirstie Haywood Senior Research Fellow RCN Research Institute, School.

Advertisements

RAHelp.org: An online intervention for rheumatoid arthritis Shigaki, C.L., 1 Smarr, K., 2,3 Siva, C., 3 Ge, B., 4 Musser, D., 5 Johnson, R. 6 1 Dept. Health.

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,

ACST-2 Ophthalmic sub-study Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Chairman, Dept. of Vascular Surgery,

Dr. Zhao TCM help Rheumatoid Arthritis. What is Rheumatoid Arthritis (RA)? RA is an autoimmune disorder inflammation of the lining of the joints. The body.

Efficacy and Safety of Tocilizumab

Patients with Rheumatoid Arthritis in Comparison to Other Connective Tissue Diseases Are Mostly Influenced by Concomitant Fibromyalgia Tomš J, Daňková.

+ Bridging the rural-urban divide for patients with rheumatoid arthritis Brenna Bath School of Physical Therapy University of Saskatchewan.

Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.

Specific effects and expectation of acupuncture treatment. A trial utilising PET imaging Dr P White Dr G Lewith Dr J Pariente Prof R Frackowiac.

C-Reactive Protein: New Applications Dr Job Ubbink, D.Sc (Pret), MRCPath (Lond) Consultant: Chemical Pathology.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.

Rheumatoid Arthritis Anila Malik GPVTS. Aims To cover the following: What is RA? Diagnostic criteria and clinical features Rheumatoid Factor Investigations.

Elizabeth Karlson, MD Associate Professor of Medicine

Rituximab for the Treatment of Rheumatoid Arthritis

Complementary and integrative Medicine; George Lewith – Professor of Health Research School for Primary Care Research The.

Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.

Hypothesis of Neural Information Flow about Acupuncture — the new methods of meridian research General Hospital of PLA ： Dr. Tong Li Dr. Ling Yin.

Core Outcome Domains for Eczema – Results of a Delphi Consensus Project Introduction Eczema is a chronic, relapsing, inflammatory skin disorder that affects.

Psoriatic Arthritis Workshop OMERACT May 14 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian.

1 Monitoring Quality of Life in the Clinic Prof. dr. Jan van Busschbach Medical Psychology and Psychotherapy Erasmus MC.

EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.

Axial Spondyloarthritis (SpA): Representative Values of Sensitivity and Specificity for Several Tests with the Resulting LRs *LR+ = sensitivity/(1 – specificity);

1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.

The Incidence and Influencing factors of functional disability in Chinese Patients with Rheumatoid Arthritis West China School Of Nursing, West China Hospital,

OMERACT Workshop Outcome Measures in Psoriatic Arthritis

Approaches for Estimating Minimally Important Differences Ron D. Hays, Ph.D. January 12, 2004 (8:50-9:10am) Minimal Clinically Important Differences in.

Outcome Measures in PsA Philip Mease MD Seattle, WA.

GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.

Mechanical signals Joint degeneration InflammationPain TARGETS mechanisms – diagnosis – therapeutics MODELS Arthritis Research UK Biomechanics and Bioengineering.

Serum Dickkopf-1 ( DKK-1) and Arthritis in Systemic Lupus Erythematosus Patients S. I. Nasef, H. H. Omar Samah Ismail Nasef MD, MRCP Rheumatology UK Lecturer.

admissions in residents in care homes.

Fibromyalgia Impact Questionnaire McGill Pain Questionnaire

SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,

Clinical outcomes among patients with chronic low back pain treated with pregabaline monotherapy in fort portal regional referral hospital, “case series”

Anti-TNF therapy improves hand function in rheumatoid arthritis

Chief investigator- Dr. Kripasindhu Gantait, Associate Professor

Pilot fMRI study of regional cerebral blood flow in RA patients before and after DMARD treatment Yvonne C. Lee1, Alexander Fine1, Ekaterina Protsenko,

NICOR A NICE Commissioned Pilot of Patient Reported Outcome Measures (PROMs) for Ablation of Cardiac Arrhythmias Withers KL 1, Patrick H 2, Cunningham.

FRAX & ITS ASSOCIATIONS IN RHEUMATOID ARTHRITIS

3e Initiative 2009 How to investigate and follow-up Undifferentiated Peripheral Inflammatory Arthritis? Case 3 1.

Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1

Sidra Hussain, Priyanka Sivakumaran Coziana Ciurtin

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Rhematoid Rthritis Respiratory disorders

Geir Smedslund, Ph.D.: Diakonhjemmet Hospital (DH)

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Clinical response in patients with early and established RA at month 24. *p

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Satisfaction with control of RA

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.

Multivariable model of adjusted

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Presentation transcript:

IMAGING NEURAL CORRELATES OF FATIGUE & PAIN IN PATIENTS WITH RA TREATED WITH TNF INHIBITORS FARHAN BARI SPR RHEUMATOLOGY WARN CONFERENCE 22 ND MAY 2014

BACKGROUND RA is an auto-immune, systemic, inflammatory condition causing pain and synovitis in the joints of the hands and feet 1 Repeated flares cause symptoms of pain, fatigue, stiffness and loss of function Fatigue has been identified by RA patients as a key problem, which they consider harder to manage than pain 2 International consensus has been reached that it should be measured in all clinical trial 3

FATIGUE IN RA Multiple and complex pathways 4 Tumour necrosis factor inhibitors (TNFi) have been shown in clinical trial to reduce fatigue Major component of fatigue is central in origin i.e. in the brain Similar to pain, fatigue is invisible and subjective fMRI has greatly advanced our understanding of pain processing in the brain Recently, in Chronic Fatigue Syndrome, it has been suggested that fatigue may also be evaluated by fMRI.

FUNCTIONAL MRI Functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. Cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases. Can be used to produce activation maps showing which parts of the brain are involved in a particular mental process.

FMRI & FATIGUE Recently, in Chronic Fatigue Syndrome, it has been suggested that fatigue may also be evaluated by fMRI 5. Calcarine fissure Cerebellum Inferior occipital sulcus Occipito-parietal cortex Posterior cingulate gyrus Parahippocampal gyrus

THE STUDY CREATE Centre in Cardiff is conducting a clinical trial funded by Erlangen University to evaluate the utility of fMRI to predict response to TNFi and to evaluate the effect of treatment on pain processing. This study aims to build on this opportunity to obtain preliminary data which can be used to assess fatigue in the brain during fMRI imaging in RA patients.

METHODOLOGY This is an observational study using fMRI as a tool to assess neural correlates of fatigue. Imaging will be undertaken pre and post TNFi in patients with RA Study duration: 24 weeks Total no. of patients: 16 Recruited from the Rheumatology Department at University Hospital of Wales. fMRI baseline and at 24 weeks, at CUBRIC centre

CLINICAL ASSESSMENTS Patient’s Assessment of Arthritis Pain (100mm visual analogue scale [VAS]) Patient’s and Physician’s Global Assessments of Arthritis (100mm VAS) Health Assessment Questionnaire-Disability Index (HAQ-DI) C-reactive protein (CRP) erythrocyte sedimentation rate (ESR) Disease activity score 28 (DAS28) Fatigue will be measured using the Bristol Rheumatoid Arthritis Fatigue Questionnaire.

CONTD Mentors: Professor Ernest Choy Professor Richard Wise Dr Ann Taylor LREC and R&D application is currently being prepared THANK YOU

REFERENCES 1.Conaghan PG, Green MJ, Emery P. Established rheumatoid arthritis. Baillières Clinical Rheumatology 1999;13: Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D et al. Patients' perceptions of fatigue in RA: Overwhelming, uncontrollable, ignored. Arthritis & Rheumatism (Arthritis Care & Research) 2005;53(5): Kirwan J, Minnock P, Adebajo A, Bresnihan B, Choy E, De Wit M et al. Patient Perspective Workshop: Fatigue as a recommended patient-centred outcome measure in rheumatoid arthritis. Journal of Rheumatology 2007;34: Hewlett S, Chalder T, Choy E, Cramp F, Davis B, Dures E, Nicholls C, Kirwan J. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford) Jun;50(6): de Lange FP1, Kalkman JS, Bleijenberg G, Hagoort P, van der Werf SP, van der Meer JW, Toni I. Neural correlates of the chronic fatigue syndrome--an fMRI study. Brain Sep;127(Pt 9): Epub 2004 Jul 7.